
SI-BONE Inc (SIBN) Stock Forecast & Price Target
SI-BONE Inc (SIBN) Analyst Ratings
Bulls say
SI-BONE is well-positioned for growth in the medical device industry, with strong financials and a positive market outlook. With a new partnership and product launches in the pipeline, the company's potential for revenue growth is promising, leading analysts to maintain a Buy recommendation and a target price of $24. However, competition and possible changes in reimbursement pose as potential risks for the company's future performance.
Bears say
SI-BONE is a company with potential for growth in the medical device market due to its unique and effective products, as evidenced by their higher than expected revenue and active physician numbers. However, there are headwinds in the short term such as weather disruptions and the onboarding of a new distributor, which may impact revenue and profitability. The company has a strategic partnership with Smith & Nephew for its trauma and spine product portfolio, which could drive further growth, but the impact may not be fully realized in the current guidance. The company has shown strong financial performance and is expected to generate positive EBITDA in 2026, but there is limited visibility into the full potential impact of the partnership at this time.
This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.
SI-BONE Inc (SIBN) Analyst Forecast & Price Prediction
Start investing in SI-BONE Inc (SIBN)
Order type
Buy in
Order amount
Est. shares
0 shares